Glytec has developed FDA-cleared software-as-a-medical-device solutions (digital therapeutics) that improve the safety and health of people with diabetes, and make insulin a more effective and accessible medication option for millions who are unable to achieve their treatment goals. The company combines evidence-based decision support technologies with expert clinical services to optimize basal and bolus insulin therapies in the hospital and at home, and in turn reduce hypoglycemia and other complications as well as avoidable ED visits, hospitalizations, readmissions and drug waste. Glytec's cloud-based glycemic management decision support system called eGMS (Glycemic Management System) enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The modular system centers on the Glucommander suite of FDA-cleared proprietary algorithms for IV, subcutaneous and pediatric insulin dosing. Management of patients requiring insulin therapy is furthered by seamless integration with EHR and connected device systems (SmartClick), robust analytics (GlucoMetrics) and surveillance (GlucoSurveillance) capabilities. eGMS interventional clinical decision support tools allow providers to standardize processes and personalize treatment across all areas of care, and are proven to result in significant improvements in clinical and financial outcomes over traditional methods. The software is designed to live within an existing EMR or on its own, tracking and analyzing glycemic data, enabling early identification of patients, efficient and effective intervention, and ongoing optimization of care, both at a hospital and at home.
Last update: April 14, 2018
Disclaimer: We can not guarantee that the information on this page is 100% correct. more